Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | P2RY1 | P47900 | 5/20 | 0.73 |
| ▸ | ENPP1 | P22413 | 3/20 | 0.73 |
| ▸ | P2RY2 | P41231 | 3/20 | 0.61 |
| ▸ | SRC | P12931 | 2/20 | 0.61 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | DNPH1 | O43598 | 1/20 | 0.61 |
| ▸ | PRKAB2 | O43741 | 1/20 | 0.61 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.61 |
| ▸ | LDHA | P00338 | 1/20 | 0.61 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.61 |
| ▸ | FBP1 | P09467 | 1/20 | 0.61 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.61 |
| ▸ | PRKAG1 | P54619 | 1/20 | 0.61 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.61 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.61 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.61 |
| ▸ | PRKAA1 | Q13131 | 1/20 | 0.61 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.61 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12850611 | 1.00 | POLB (0.77) | POLBP2RY1ENPP1P2RY2SRC | |
| SCHEMBL18785113 | 0.93 | POLB (0.81) | POLBP2RY1ENPP1P2RY2SRC | |
| SCHEMBL48174 | 0.93 | POLB (0.81) | POLBP2RY1ENPP1P2RY2SRC | |
| SCHEMBL20341113 | 0.93 | POLB (0.81) | POLBP2RY1ENPP1P2RY2SRC | |
| SCHEMBL11927745 | 0.93 | POLB (0.81) | POLBP2RY1ENPP1P2RY2SRC | |
| SCHEMBL7882477 | 0.93 | POLB (0.81) | POLBP2RY1ENPP1P2RY2SRC | |
| SCHEMBL4546151 | 0.93 | POLB (0.81) | POLBP2RY1ENPP1P2RY2SRC | |
| SCHEMBL543475 | 0.93 | POLB (0.81) | POLBP2RY1ENPP1P2RY2SRC | |
| Water SCHEMBL112387 | 0.92 | POLB (0.79) | POLBP2RY1ENPP1P2RY2SRC | |
| SCHEMBL25780740 | 0.92 | POLB (0.73) | POLBP2RY1ENPP1P2RY2SRC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9951334-B2 | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field | NOGRA PHARMA LIMITED (IE) | 2018-04-24 | — | — | US | claimed |
| US-20180030450-A1 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field | GIULIANI INTERNATIONAL, LTD. (IE) | 2018-02-01 | — | — | US | claimed |
| US-9518264-B2 | Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field | NOGRA PHARMA LIMITED (IE) | 2016-12-13 | — | — | US | claimed |
| US-20160304876-A1 | Antisense Oligonucleotides (ODN) Against SMAD7 and Uses Thereof in Medical Field | GIULIANI INTERNATIONAL, LTD. (IE) | 2016-10-20 | — | — | US | claimed |
| US-20180289692-A1 | TLR MODULATORS AND METHODS OF USE | NOGRA PHARMA LIMITED (IE) | 2018-10-11 | — | — | US | disclosed |
| US-20180168208-A1 | FLAVOR COMPOSITIONS AND PET FOOD PRODUCTS CONTAINING THE SAME | MARS, INCORPORATED (US) | 2018-06-21 | — | — | US | disclosed |
| WO-2015168514-A1 | METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS | ISIS PHARMACEUTICALS, INC. (US) | 2015-11-05 | — | — | WO | disclosed |
| EP-0690716-A4 | OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACID pH | UNIV JOHNS HOPKINS (US) | 1997-05-02 | — | — | EP | disclosed |
| EP-0690716-A1 | OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACID pH | THE JOHNS HOPKINS UNIVERSITY (US) | 1996-01-10 | — | — | EP | disclosed |
| WO-1994015619-A1 | OLIGONUCLEOTIDES MODIFIED TO IMPROVE STABILITY AT ACID pH | THE JOHNS HOPKINS UNIVERSITY (US) | 1994-07-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180289692-A1 | TLR MODULATORS AND METHODS OF USE | TLR7, TLR3, TLR9 | POLB 1894/4885P2RY1 1524/4885ENPP1 2337/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.